Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 27;5(1):e8884.
doi: 10.1371/journal.pone.0008884.

Risk of ovarian cancer and inherited variants in relapse-associated genes

Abraham Peedicayil  1 , Robert A Vierkant, Lynn C Hartmann, Brooke L Fridley, Zachary S Fredericksen, Kristin L White, Elaine A Elliott, Catherine M Phelan, Ya-Yu Tsai, Andrew Berchuck, Edwin S Iversen Jr, Fergus J Couch, Prema Peethamabaran, Melissa C Larson, Kimberly R Kalli, Matthew L Kosel, Vijayalakshmi Shridhar, David N Rider, Mark Liebow, Julie M Cunningham, Joellen M Schildkraut, Thomas A Sellers, Ellen L Goode
Affiliations

Risk of ovarian cancer and inherited variants in relapse-associated genes

Abraham Peedicayil et al. PLoS One. .

Abstract

Background: We previously identified a panel of genes associated with outcome of ovarian cancer. The purpose of the current study was to assess whether variants in these genes correlated with ovarian cancer risk.

Methods and findings: Women with and without invasive ovarian cancer (749 cases, 1,041 controls) were genotyped at 136 single nucleotide polymorphisms (SNPs) within 13 candidate genes. Risk was estimated for each SNP and for overall variation within each gene. At the gene-level, variation within MSL1 (male-specific lethal-1 homolog) was associated with risk of serous cancer (p = 0.03); haplotypes within PRPF31 (PRP31 pre-mRNA processing factor 31 homolog) were associated with risk of invasive disease (p = 0.03). MSL1 rs7211770 was associated with decreased risk of serous disease (OR 0.81, 95% CI 0.66-0.98; p = 0.03). SNPs in MFSD7, BTN3A3, ZNF200, PTPRS, and CCND1A were inversely associated with risk (p<0.05), and there was increased risk at HEXIM1 rs1053578 (p = 0.04, OR 1.40, 95% CI 1.02-1.91).

Conclusions: Tumor studies can reveal novel genes worthy of follow-up for cancer susceptibility. Here, we found that inherited markers in the gene encoding MSL1, part of a complex that modifies the histone H4, may decrease risk of invasive serous ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

  • Inherited common variants in mitochondrial DNA and invasive serous epithelial ovarian cancer risk.
    Earp MA, Brooks-Wilson A, Cook L, Le N. Earp MA, et al. BMC Res Notes. 2013 Oct 22;6:425. doi: 10.1186/1756-0500-6-425. BMC Res Notes. 2013. PMID: 24148579 Free PMC article.
  • Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer.
    Peedicayil A, Vierkant RA, Shridhar V, Schildkraut JM, Armasu S, Hartmann LC, Fridley BL, Cunningham JM, Phelan CM, Sellers TA, Goode EL. Peedicayil A, et al. Gynecol Oncol. 2009 Aug;114(2):260-4. doi: 10.1016/j.ygyno.2009.03.038. Epub 2009 May 5. Gynecol Oncol. 2009. PMID: 19419758 Free PMC article.
  • Inherited determinants of ovarian cancer survival.
    Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC. Goode EL, et al. Clin Cancer Res. 2010 Feb 1;16(3):995-1007. doi: 10.1158/1078-0432.CCR-09-2553. Epub 2010 Jan 26. Clin Cancer Res. 2010. PMID: 20103664 Free PMC article.
  • Common variants in mismatch repair genes and risk of invasive ovarian cancer.
    Song H, Ramus SJ, Quaye L, DiCioccio RA, Tyrer J, Lomas E, Shadforth D, Hogdall E, Hogdall C, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjaer SK, Pharoah PD, Gayther SA. Song H, et al. Carcinogenesis. 2006 Nov;27(11):2235-42. doi: 10.1093/carcin/bgl089. Epub 2006 Jun 13. Carcinogenesis. 2006. PMID: 16774946
  • BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
    Kelemen L, James M, Spurdle A, Campbell I, Chang-Claude J, Peel D, Anton-Culver H, Berchuck A, Schildkraut J, Whittemore A, McGurie V, DiCioccio RA, Duffy D, Chenevix-Trench G. Kelemen L, et al. Gynecol Oncol. 2005 Jun;97(3):807-12. doi: 10.1016/j.ygyno.2005.03.007. Gynecol Oncol. 2005. PMID: 15904951
See all similar articles

Cited by

  • Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer.
    Lebrero-Fernández C, Wenzel UA, Akeus P, Wang Y, Strid H, Simrén M, Gustavsson B, Börjesson LG, Cardell SL, Öhman L, Quiding-Järbrink M, Bas-Forsberg A. Lebrero-Fernández C, et al. Immun Inflamm Dis. 2016 Apr 1;4(2):191-200. doi: 10.1002/iid3.105. eCollection 2016 Jun. Immun Inflamm Dis. 2016. PMID: 27957327 Free PMC article.
  • OMICfpp: a fuzzy approach for paired RNA-Seq counts.
    Berral-Gonzalez A, Riffo-Campos AL, Ayala G. Berral-Gonzalez A, et al. BMC Genomics. 2019 Apr 2;20(1):259. doi: 10.1186/s12864-019-5496-5. BMC Genomics. 2019. PMID: 30940089 Free PMC article.
  • Immune modulation by butyrophilins.
    Arnett HA, Viney JL. Arnett HA, et al. Nat Rev Immunol. 2014 Aug;14(8):559-69. doi: 10.1038/nri3715. Nat Rev Immunol. 2014. PMID: 25060581 Review.
  • Assessment of hepatocyte growth factor in ovarian cancer mortality.
    Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Høgdall E, Kjær SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Høgdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA; Ovarian Cancer Association Consortium. Goode EL, et al. Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1638-48. doi: 10.1158/1055-9965.EPI-11-0455. Epub 2011 Jul 1. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21724856 Free PMC article.
  • NLRC5 promotes transcription of BTN3A1-3 genes and Vγ9Vδ2 T cell-mediated killing.
    Dang AT, Strietz J, Zenobi A, Khameneh HJ, Brandl SM, Lozza L, Conradt G, Kaufmann SHE, Reith W, Kwee I, Minguet S, Chelbi ST, Guarda G. Dang AT, et al. iScience. 2020 Dec 7;24(1):101900. doi: 10.1016/j.isci.2020.101900. eCollection 2021 Jan 22. iScience. 2020. PMID: 33364588 Free PMC article.
See all "Cited by" articles

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. - PubMed
    1. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005;11(6):2149–2155. - PubMed
    1. De Smet F, Pochet NL, De Moor BL, Van Gorp T, Timmerman D, et al. Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles. Clin Cancer Res. 2005;11(21):7958–7959; author reply 7959. - PubMed
    1. Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat. 2007;28(12):1207–1215. - PubMed
    1. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Molecular oncology. 2009;3(2):97–137. - PMC - PubMed

Publication types